Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Poor Supplier Control Causing Recalls, FDA Says; Contract Is Key To Success

This article was originally published in The Silver Sheet

Executive Summary

SUPPLIER CONTROL PROBLEMS ARE ON THE RISE and may be contributing to an increase in medical device recalls, says FDA Quality Systems Expert Kim Trautman. "When the recalls come in and [firms are] identifying some of the causes for the recall, it seems to be more prevalent within the past five or so years that they are supplier issues," she notes. To combat the trend, FDA has begun emphasizing to industry the importance of complying with purchasing controls, as well as ensuring that supplier contracts adequately outline product and service requirements. "Sometimes the contracts and the expectations between the finished device manufacturer and the supplier are just too loose," Trautman says. Meanwhile, the agency admits it is having a tough time keeping up with "virtual manufacturing" and "internal supplying" arrangements...

You may also be interested in...



QUOTED. 13 December 2019. Todd Garner

ConMed's CFO Todd Garner told delegates at the Jefferies Healthcare conference that the company's orthopedic franchise is focused on its pipeline and meeting customer's needs.  See what the CFO said about it here.

Sarepta Scores Another Remarkable Approval With Vyondys 53 For Duchenne

Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.

Real-World Evidence Fails Another Test At US FDA

Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.

Topics

UsernamePublicRestriction

Register

MT036120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel